Joaquin Martinez‐Lopez
A5101631428- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Protein Degradation and Inhibitors
- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Kruppel-like factors research
- Quinazolinone synthesis and applications
- Immunodeficiency and Autoimmune Disorders
- Cancer therapeutics and mechanisms
- Lymphoma Diagnosis and Treatment
Centro de Investigación Biomédica en Red de Cáncer
2025
Hospital Universitario 12 De Octubre
2013-2025
Abstract Polycythemia vera (PV) is a myeloproliferative neoplasm associated with high symptom and psychological burden, resulting in decreased quality of life (QoL). Patients PV have an increased risk cardiovascular (CV) complications, making regular monitoring crucial. The Landmark 2.0 survey was conducted worldwide among patients their treating physicians to identify any potential gaps perceptions regarding management. Data were collected between April 2021 2022 from across 11 countries....
Abstract In chronic lymphocytic leukemia, the reliability of next‐generation sequencing (NGS) to detect TP53 variants ≤10% allelic frequency (low‐VAF) is debated. We tested ability 23 such in 41 different laboratories using their NGS method choice. The sensitivity was 85.6%, 94.5%, and 94.8% at 1%, 2%, 3% VAF cut‐off, respectively. While only one false positive (FP) result reported >2% VAF, it more challenging distinguish true <2% from background noise (37 FPs by 9 laboratories)....
Summary Real‐world data (RWD) previously contributed to post‐marketing regulatory decision‐making, but are currently also considered as external controls single‐arm trials. The use of RWD control may be compromised by methodological issues, urging validation cohorts. Two cohorts newly diagnosed acute myeloid leukaemia patients, one registered the HARMONY Alliance (HA) and Netherlands Cancer Registry (NCR), were compared arm randomized HOVON‐103 trial (H103 controls). All aged >65 years...
Perifosine, an investigational, oral, synthetic alkylphospholipid, inhibits signal transduction pathways of relevance in multiple myeloma (MM) including PI3K/Akt. Perifosine demonstrated anti-MM activity preclinical studies and encouraging early-phase clinical combination with bortezomib. A randomized, double-blind, placebo-controlled phase 3 study was conducted to evaluate addition perifosine bortezomib-dexamethasone MM patients one four prior therapies who had relapsed following previous...